Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response aligns with the label on core indications, mechanism, and certain safety alerts (e.g., contraindication with aliskiren in diabetics, hyperkalemia risk), and notes combination with diuretics. However, it includes multiple non-label claims (brand and patent history, direct efficacy magnitudes, onset timelines, brand-specific formulations) and several head-to-head efficacy/comparative statements not supported by the label. Overall, partial alignment with notable non-label additions.
Category Scores
Accurate Statements
Losartan lowers blood pressure.
1.1 Hypertension
Losartan is an angiotensin II receptor blocker (ARB).
12.1 Mechanism of Action
Losartan relaxes blood vessels by blocking angiotensin II, a hormone that narrows them.
12.1 Mechanism of Action
This reduces resistance to blood flow, decreasing systolic and diastolic pressure.
12.1 Mechanism of Action; 1.1 Hypertension
Effects are noticeable within 1-2 weeks.
1.1 Hypertension
Losartan should be avoided with aliskiren in diabetics.
4 Contraindications
Use caution with NSAIDs.
7 Drug Interactions
Use caution with potassium supplements.
5.4 Hyperkalemia
It pairs well with diuretics like hydrochlorothiazide in combo pills (e.g., Hyzaar).
1.1 Hypertension
Losartan is used for hypertension and kidney protection.
1.1 Hypertension; 1.3 Nephropathy in Type 2 Diabetic Patients
Rare risks include high potassium, kidney issues, or angioedema.
5.4 Hyperkalemia; 5.3 Renal Function Deterioration; 6 Adverse Reactions
Unsupported Statements
Clinical trials show losartan reduces systolic blood pressure by 8-13 mmHg and diastolic by 6-8 mmHg on average.
Absent from label
Effects peak at 3-6 weeks.
Absent from label
Losartan works similarly to other ARBs like valsartan.
Absent from label
Losartan differs from ACE inhibitors (e.g., lisinopril), which it often replaces to avoid cough side effects.
Absent from label
Compared to calcium channel blockers like amlodipine, losartan provides comparable reductions but may better protect kidneys in diabetic patients.
Absent from label
Losartan is sold as Cozaar.
Absent from label
Losartan was originally developed by Merck.
Absent from label
Generics from Teva, Sandoz, and others dominate since patent expiry in 2010 for the base compound.
Absent from label
No active patents block generics.
Absent from label
Check DrugPatentWatch.com for formulation-specific extensions.
Absent from label
Common effects include dizziness (4%), back pain (3%), and nasal congestion (2%).
Absent from label
It lowers BP more in salt-depleted patients, risking hypotension.
Absent from label
Full effect in 3-6 weeks.
Absent from label
Some drop within hours of the first dose.
Absent from label
Take once daily.
Absent from label
Missed doses may cause rebound hypertension.
Absent from label
Contradictions
Important Omissions
Boxed warning for pregnancy (8.1 Pregnancy) and explicit use in pregnancy; pediatric safety data (8 Pediatric Use) are not reflected in user claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Most accurately labeled safety information is captured (e.g., hyperkalemia, renal monitoring, aliskiren contraindication); non-label claims introduce potential misinterpretation but do not indicate high immediate risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Inclusion of non-label information (brand name, patent history, direct efficacy comparisons, general labeling-off-label statements) reduces label fidelity.
Suggested Improvement
Limit statements to label-approved indications, mechanisms, contraindications, warnings, drug interactions, and administration details; exclude historical patent information and non-label efficacy comparisons; ensure any onset or dosing statements are explicitly supported by the label.